Trimel Pharmaceuticals Investor Event – Webcast
On May 28, 2014 Trimel Pharmaceuticals announced the successful results of its Phase II clinical trial evaluating the efficacy of Tefina™, a “use-as-required” therapy for the treatment of female orgasmic disorder.
At the Trimel Pharmaceuticals Investor Event on June 12, 2014 President and CEO Tom Rossi joined company executives as well as Dr. Sheryl Kingsberg to present additional data from the completed Phase II Tefina™ study.
Dr. Kingsberg provided an overview of female sexual dysfunction and, in particular, female orgasmic disorder, as well as presented the significance of the positive Phase II results for Tefina™. Dr. Kingsberg was the U.S. principal investigator for the Tefina™ Phase II clinical trial and is the chief of behavioral medicine at University Hospitals Case Medical Center and professor of reproductive biology and psychiatry at Case Western Reserve University in Cleveland, Ohio.
To view the Trimel Pharmaceuticals Investor Event webcast, held on June 12, 2014, please click here.